Dive into the latest insights from our top experts and stay updated with the most recent developments in market access.
MMIT (Managed Markets Insight & Technology)
Information Services
Yardley, Pennsylvania 47,628 followers
About us
For nearly two decades MMIT has been solely focused on solving the “what and why” of drug coverage and has been a trusted, go-to-market partner to pharma companies, payers and providers. We believe that patients who need lifesaving treatments shouldn’t face delays because accessing drugs can be confusing. As the leading provider of market access data, analytics and insights, our expert teams of clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. Divisions of MMIT include AIS Health, creator of the Directory of Health Plans and leading healthcare publications; Zitter Health Insights, a preeminent provider of market access insights and solutions for specialty drugs; RJ Health, the market leader in pricing and coding solutions for infusion drugs covered under the medical benefit; and The Dedham Group, a U.S. market access oncology and specialty therapeutics consultancy offering research, data analytics and strategy formulation services to the life sciences industry.
- Website
-
http://www.mmitnetwork.com
External link for MMIT (Managed Markets Insight & Technology)
- Industry
- Information Services
- Company size
- 201-500 employees
- Headquarters
- Yardley, Pennsylvania
- Type
- Privately Held
- Specialties
- Formulary, Policy & Restriction Transparency, Mobile Formulary Search Application, Launch Commercialization Guidance, and Formulary Management & Publishing
Locations
Employees at MMIT (Managed Markets Insight & Technology)
Updates
-
In the latest issue of Radar on Specialty Pharmacy, industry experts reflect on this year's trends in pharmacy and medical benefit management as more specialty drugs and cell and gene therapies hit the U.S. market. https://hubs.ly/Q0301qlG0
-
-
See how HCP Message Monitor helped a pharma manufacturer understand message effectiveness and ensure recall in our latest case study. https://ow.ly/UmC750TQitM
-
-
In this use case, learn how MMIT, powered by NorstellaLinQ, translated complex RWD into actionable strategies to help a client achieve business growth while advancing equity and patient access. https://ow.ly/7Zsz50Ut1GI #MarketAccess #RWD #PatientAccess Norstella
-
-
Citing “substantial and unmitigable costs” that were driven partly by increasing risk scores, CMS has announced plans to shut down the Medicare Advantage Value-Based Insurance Design (VBID) model at the end of 2025. For a complete view of the model's history, check out this comprehensive timeline from AIS Health, a division of MMIT. #medicareadvantage #vbid https://hubs.ly/Q02_YxF70
VBID Update Dec 2024 - Infogram
https://infogram.com/
-
By 2025, most doctors and cancer specialists anticipate a rise in the use of biosimilars across various medical conditions. https://ow.ly/TRF150TQ85X Samantha Ngan from MMIT provides valuable insights into the current research on biosimilar trends, the timing of payer exclusions of reference products, and key takeaways from the competitive Humira biosimilar market. Click the link in this post for the full article.
-
-
Making sense of access data can be a time and resource-consuming challenge. Learn how MMIT can help your team simplify the process. https://ow.ly/TZjP50TQi4y
-
-
New in the December issue of Radar on Specialty Pharmacy: https://hubs.ly/Q02_tZy60 Why payers took a more active role in specialty drug management this year, 2024's defining specialty pharmacy trends, how UCB's Bimzelx will impact the psoriatic arthritis market, and more top stories. #Pipeline2Patient Norstella
-
-
More pharma companies are entering into warranty-based contracts with payers to mitigate the risk of high-cost specialty therapies. https://ow.ly/G5z850Uq1YN MMIT’s Samantha Ngan shares the latest research on payers' attitudes toward these arrangements and when pharma companies should consider them. #PharmaContracts #SpecialtyTherapies #PharmaceuticalIndustry #PharmaTrends
-
-
Despite its cost, Wegovy is currently covered at 54% across all channels, according to MMIT’s payer policy and restriction data. MMIT’s Autumn Bowman looks at coverage trends in this high-growth market: https://ow.ly/WaJO50SyXHl.
-